iBio (IBIO)
(Delayed Data from AMEX)
$1.90 USD
+0.15 (8.57%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $1.91 +0.01 (0.53%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for iBio, Inc falls in the month of June.
All items in Millions except Per Share data.
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 7 | 34 | 97 | 55 | 4 |
Receivables | 0 | 6 | 6 | 6 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 4 | 0 | 1 | 0 |
Other Current Assets | 19 | 2 | 2 | 0 | 0 |
Total Current Assets | 26 | 45 | 105 | 62 | 5 |
Net Property & Equipment | 4 | 37 | 9 | 4 | 24 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 2 | 2 | 7 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 5 | 5 | 1 | 1 | 1 |
Deposits & Other Assets | 0 | 6 | 0 | 0 | 0 |
Total Assets | 41 | 99 | 147 | 94 | 31 |
Liabilities & Shareholders Equity | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 1 | 0 | 0 |
Accounts Payable | 2 | 4 | 2 | 2 | 1 |
Current Portion Long-Term Debt | 13 | 22 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 4 | 3 | 1 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 0 | 0 | 2 | 1 |
Total Current Liabilities | 22 | 30 | 7 | 5 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 32 | 32 | 25 |
Other Non-Current Liabilities | 1 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 26 | 36 | 38 | 38 | 28 |
Shareholders Equity | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 304 | 288 | 282 | 207 | 108 |
Retained Earnings | -289 | -224 | -174 | -150 | -106 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 15 | 63 | 109 | 57 | 2 |
Total Liabilities & Shareholder's Equity | 41 | 99 | 147 | 94 | 31 |
Total Common Equity | 15 | 63 | 109 | 57 | 2 |
Shares Outstanding | 1.00 | 0.40 | 0.40 | 0.20 | 0.00 |
Book Value Per Share | 15.38 | 158.73 | 271.43 | 283.05 | 2.46 |
Fiscal Year End for iBio, Inc falls in the month of June.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 4 | 5 | 7 | 7 |
Receivables | NA | 0 | 0 | 0 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 16 | 19 | 19 | 19 |
Total Current Assets | NA | 20 | 23 | 26 | 27 |
Net Property & Equipment | NA | 4 | 4 | 4 | 4 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 2 | 2 | 2 | 1 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 5 | 5 | 5 | 5 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 3 |
Total Assets | NA | 34 | 38 | 41 | 44 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 2 | 2 | 2 |
Current Portion Long-Term Debt | NA | 13 | 13 | 13 | 14 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 4 | 3 | 4 | 4 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 2 | 2 | 2 | 2 |
Total Current Liabilities | NA | 22 | 21 | 22 | 22 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 1 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 25 | 24 | 26 | 27 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 312 | 308 | 304 | 300 |
Retained Earnings | NA | -303 | -295 | -289 | -283 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 9 | 13 | 15 | 17 |
Total Liabilities & Shareholder's Equity | NA | 34 | 38 | 41 | 44 |
Total Common Equity | 0 | 9 | 13 | 15 | 17 |
Shares Outstanding | 3.40 | 3.20 | 1.40 | 1.00 | 0.70 |
Book Value Per Share | 0.00 | 2.88 | 9.44 | 15.38 | 24.84 |